chartexchange

Solid Biosciences Reports Third Quarter 2026 Financial Results and Provides Business Updates

GlobeNewswire Inc. | Nov 4, 2026 4:07 PM EST

-  Duchenne (SGT-003): SGT-003 has been generally well tolerated in the 53 participants dosed in the Phase 1/2 INSPIRE DUCHENNE clinical trial as of November 3, 2026 -

Read original article